Record-High Net Product Revenue of $44.9 Million
in Second Quarter
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health, today announced
financial results for the three and six months ended June 30, 2017,
and provided an update on company operations.
Key Amarin achievements since March 31, 2017 include:
- Product revenue growth: Recognized $44.9 million in U.S. net
product revenue from Vascepa® (icosapent ethyl) sales in Q2 2017
compared to $32.8 million in Q2 2016, an increase of 37%.
- U.S. prescription growth: Increased normalized prescriptions
for Vascepa by 50% and 52% compared to Q2 2016 based on data from
Symphony Health Solutions and IMS Health, respectively.
- R&D progress: Landmark long-term cardiovascular outcomes
study, REDUCE-IT, nearing completion with results expected to be
reported in Q2 or Q3 of 2018.
- Cash flow: Net cash flow was modestly positive from operations
during three and six months ended June 30, 2017, excluding cash
flow related to R&D and finance (i.e., excluding cash
inflows/outflows from debt-related transactions reported in Q1
2017, interest and royalty).
- Cash balance: As of June 30, 2017, Amarin had a cash balance of
$85.5 million.
“We believe evidence continues to mount supporting the potential
success of the REDUCE-IT cardiovascular outcomes study and that
Amarin is at the forefront of what could become a new era in
preventative cardiovascular care. We have also seen increased
interest in addressing residual cardiovascular risk beyond
controlling LDL-cholesterol, and a greater focus on finding
treatments that can help address this risk,” stated John F. Thero,
president and chief executive officer. “This is an exciting time
for Amarin both with respect to growing current revenues and
contemplation of the broader positive effect that Vascepa could
have on improving patient care if REDUCE-IT study results, expected
approximately a year from now, are consistent with expectations. We
will continue to focus on positive execution.”
Dr. Craig Granowitz, chief medical officer, noted, “Recent
studies of add-ons to statin therapy illuminate the need to address
the significant residual cardiovascular risk beyond managing
LDL-cholesterol.” Dr. Granowitz continued, “While multiple new
therapies are in development to address the various medical needs
of patients at-risk for cardiovascular disease, if REDUCE-IT is
successful in its studied population, we see several practical
advantages favoring increased Vascepa use following successful
outcomes study results. Vascepa already has years of post-approval
market experience that support its favorable safety and
tolerability profile. It also has a convenient oral dosage form, an
affordable price and broad managed care coverage. These attributes
position Vascepa well to help more patients and potentially become
a standard of care therapy following positive REDUCE-IT
results.”
Substantial commercial growth continues
Our commercial team again drove new and recurring Vascepa
prescription growth in the second quarter of 2017. This growth,
which was aided by expanded managed care coverage at the start of
2017, reflects further productivity improvement from our U.S. sales
team, the size of which has remained consistent since the end of
2013.
Estimated normalized total Vascepa prescriptions, based on data
from Symphony Health Solutions and IMS Health, totaled
approximately 344,000 and 372,000, respectively, for the three
months ended June 30, 2017. These prescription levels represent
growth of approximately 50% and 52%, respectively, from prior year
levels.
REDUCE-IT trial status
The REDUCE-IT cardiovascular outcomes trial continues to
progress towards reported results in Q2 or Q3 of 2018, assuming the
trial is not stopped early. Based on historical event rates,
Amarin anticipates the study reaching in early 2018 the onset of
100% of the targeted cumulative total of 1,612 primary major
adverse cardiovascular events (MACE). Reaching this events target
will be followed by final patient visits to clinical sites,
accumulation of final data, including on any primary or other
categories of MACE that have been documented and adjudicated, and
final efficacy and safety data review by the independent review
committees and the REDUCE-IT operational team. After Amarin
is unblinded and learns the results of the study, the results will
be publicly communicated. Amarin believes that the results of this
landmark trial, if successful, could lead to improved preventative
medical care for tens of millions of patients and could contribute
to significantly lower costs for treating these patients.
REDUCE-IT is the first prospectively conducted, multi-national,
double-blinded study to evaluate the effects of treating patients
who despite well-controlled LDL-cholesterol have high triglycerides
and other risk factors associated with cardiovascular
disease. This 8,175-patient study, which commenced in late
2011, has accumulated over 30,000 years of study of treated
patients. Amarin seeks to determine whether the potentially broad
clinical effects of an intentionally high daily dose (4 grams per
day) of Vascepa translate into fewer cardiovascular events for
at-risk patients. If successful in demonstrating positive
cardiovascular outcomes results, Amarin believes that Vascepa is
well-positioned to be prescribed for treatment of at-risk patients
due to the efficacy, tolerability, ease of administration and
affordable price of Vascepa.
Later in the current quarter (Q3 2017), Amarin anticipates
receiving the recommendation of the independent data monitoring
committee (DMC) regarding its pre-scheduled interim efficacy and
safety analysis. In this analysis, the DMC will review data
available from the preparations triggered by the onset of
approximately 80% of targeted primary MACE. As is typical in
cardiovascular outcomes studies, Amarin expects the DMC to
recommend that this important study should continue to completion
which, as planned, is expected to provide a more robust result
based on the larger number of MACE at the end of the trial.
The thresholds for early trial stoppage due to overwhelming
efficacy are intentionally high with respect to both quantitative
and qualitative measures. Amarin is operating with the expectation
that the trial will continue to completion.
Amarin will remain blinded to the interim and ongoing results of
the REDUCE-IT study as well as to any interim p-values and other
statistical information until after the study is ready to be
stopped and the database is locked, either at the interim analysis
or at the final analysis.
Financial update
Net product revenue for the three months ended June 30, 2017 and
2016 was $44.9 million and $32.8 million, respectively. Net product
revenue for the six months ended June 30, 2017 and 2016 was $79.3
million and $58.1 million, respectively. As reported in conjunction
with results from Q2 2016, an increase in wholesaler inventory
levels, calculated on a days-on-hand basis, resulted in a net
overall increase in product revenues of approximately $2.9 million
to $3.2 million. During Q2 2017, wholesaler inventory levels
decreased modestly calculated on the same basis. On a pro
forma basis, adjusting for the impact of the change in wholesaler
inventory levels, net product revenue growth in Q2 2017 as compared
to Q2 2016 would have been consistent with reported total
prescription (TRx) growth. At the end of Q2 2017, inventory levels
at these independent wholesalers are believed to be within a normal
range for the industry.
Based on year-to-date results and anticipated trends, Amarin is
increasing its guidance estimate for total 2017 net product revenue
to $165.0 million to $175.0 million. Amarin expects continued TRx
growth to drive increased full-year 2017 revenue despite the
potential impact of periodic fluctuations in wholesaler inventory
levels.
Licensing revenue, which relates to agreements for the
commercialization of Vascepa outside the United States, during the
six months ended June 30, 2017 and 2016 was $0.6 million and $0.5
million, respectively. The amount of licensing revenue recorded may
be variable from period to period based on changes in estimates of
the timing and level of support required.
Our gross margin on product sales for the three and six months
ended June 30, 2017 and 2016 was 75% and 73%, respectively.
This improvement was primarily driven by lower unit cost API
purchases.
Selling, general and administrative expense for the six months
ended June 30, 2017 and 2016 was $65.7 million and $54.1 million,
respectively, an increase of $11.6 million, or 22%. The increase is
due primarily to increased co-promotion fees resulting from
increased sales, increased promotional activities and increased
legal costs, which are subject to quarterly variability.
Research and development expense for the six months ended June
30, 2017 and 2016 was $24.5 million and $26.3 million,
respectively, a decrease of $1.8 million, or 7%. The decrease in
research and development expenses for the six months ended June 30,
2017, as compared to the prior year period, is primarily due to
timing of REDUCE-IT and related
costs.
Under GAAP, Amarin reported a net loss of $13.6 million in the
three months ended June 30, 2017, or basic and diluted loss per
share of $0.05. This net loss included $3.6 million in non-cash
stock-based compensation expense. Amarin reported a net loss of
$13.4 million in the three months ended June 30, 2016, or basic and
diluted loss per share of $0.07. This net loss included $3.4
million in non-cash stock-based compensation expense and a $5.8
million non-cash gain on the change in fair value of
derivatives.
Under GAAP, Amarin reported a net loss of $34.6 million in the
six months ended June 30, 2017, or basic and diluted loss per share
of $0.13. This net loss included $7.0 million in non-cash
stock-based compensation expense. For the six months ended June 30,
2016, Amarin reported a net loss of $43.1 million, or basic and
diluted loss per share of $0.23. This net loss included $7.0
million in non-cash stock-based compensation expense and a $4.6
million non-cash gain on the change in fair value of
derivatives.
Amarin reported cash and cash equivalents of $85.5 million at
June 30, 2017. Net cash flow from operations, excluding debt
restructuring, interest and royalties, and R&D costs, in the
three and six months ended June 30, 2017 was modestly positive. On
this basis, the company anticipates that net cash flow for 2017
will be positive; however, the company expects continued
variability due to the timing of certain items, including purchases
of API. For the six months ended June 30, 2017, cash outflows
relating to research and development were approximately $20.8
million and cash paid for interest and royalties, in aggregate, was
approximately $7.5 million.
As of June 30, 2017, the company had $37.5 million in net
accounts receivable ($48.4 million in gross accounts receivable
before allowances and reserves), which are current and $24.8
million in inventory. As of June 30, 2017, the company had accounts
payable and accrued expenses of $65.6 million which increased from
$43.8 million at December 31, 2016 primarily due to the timing of
rebate and certain supplier payments.
As of June 30, 2017, Amarin had approximately 270.8 million
American Depository Shares (ADSs) and ordinary shares outstanding,
32.8 million common share equivalents of Series A Convertible
Preferred Shares outstanding and approximately 23.7 million
equivalent shares underlying stock options at a weighted-average
exercise price of $3.25, as well as 12.1 million equivalent shares
underlying restricted or deferred stock units.
Conference call and webcast information
Amarin will host a conference call at 8:00 a.m.
ET today, August 2, 2017. The call will be webcast
live with slides and accessible through the investor relations
section of the company’s website at www.amarincorp.com, or via
telephone by dialing 877-407-8033 within the United States or
201-689-8033 from outside the United States. A replay of the call
will be made available for a period of two weeks following the
conference call. To hear a replay of the call, dial 877-481-4010
(inside the United States) or 919-882-2331 (outside the United
States). A replay of the call will also be available through the
company's website shortly after the call. For both dial-in numbers
please use PIN: 16156.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development program
leverages its extensive experience in lipid science and the
potential therapeutic benefits of polyunsaturated fatty
acids. Amarin's clinical program includes a commitment to an
ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's
first FDA approved product, is a highly-pure, omega-3 fatty acid
product available by prescription. Amarin has been issued
multiple patents internationally based on the unique clinical
profile of Vascepa, including the drug’s ability to lower
triglyceride levels in relevant patient populations without raising
LDL-cholesterol levels. For more information about Vascepa,
visit www.vascepa.com. For more information about Amarin,
visit www.amarincorp.com.
About Vascepa® (icosapent ethyl) capsules
Vascepa® (icosapent ethyl) capsules are a single-molecule
prescription product consisting of the omega-3 acid commonly known
as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived
from fish through a stringent and complex FDA-regulated
manufacturing process designed to effectively eliminate impurities
and isolate and protect the single molecule active ingredient.
Vascepa is known in scientific literature as AMR101.
FDA-Approved Indication and Usage
- Vascepa (icosapent ethyl) is indicated as an adjunct to diet to
reduce triglyceride (TG) levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia.
- The effect of Vascepa on the risk for pancreatitis and
cardiovascular mortality and morbidity in patients with severe
hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
- Vascepa is contraindicated in patients with known
hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of
its components.
- Use with caution in patients with known hypersensitivity to
fish and/or shellfish.
- The most common reported adverse reaction (incidence > 2%
and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0%
for placebo). There was no reported adverse reaction > 3% and
greater than placebo.
- Patients receiving treatment with Vascepa and other drugs
affecting coagulation (e.g., anti-platelet agents) should be
monitored periodically.
- In patients with hepatic impairment, monitor ALT and AST levels
periodically during therapy.
- Patients should be advised to swallow Vascepa capsules whole;
not to break open, crush, dissolve, or chew Vascepa.
- Adverse events and product complaints may be reported by
calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT
WWW.VASCEPA.COM.
Vascepa has been approved for use by the United States Food and
Drug Administration (FDA) as an adjunct to diet to reduce
triglyceride levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia. Vascepa is under various stages of
development for potential use in other indications that have not
been approved by the FDA. Nothing in this press release should be
construed as promoting the use of Vascepa in any indication that
has not been approved by the FDA.
Forward-looking statements
This press release contains forward-looking statements,
including expectations regarding revenue growth, spending levels
and cash flow as well as REDUCE-IT related expectations for
continued event rates, interim data review, results and related
timing and announcements; expectations related to the final
outcomes of the REDUCE-IT study and the anticipated successful
completion of the REDUCE-IT study; and statements regarding the
potential and therapeutic benefits of Vascepa. These
forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. In particular, as
disclosed in filings with the U.S. Securities and Exchange
Commission, Amarin's ability to effectively develop and
commercialize Vascepa will depend in part on its ability to
continue to effectively finance its business, efforts of third
parties, its ability to create market demand for Vascepa through
education, marketing and sales activities, to achieve increased
market acceptance of Vascepa, to receive adequate levels of
reimbursement from third-party payers, to develop and maintain a
consistent source of commercial supply at a competitive price, to
comply with legal and regulatory requirements in connection with
the sale and promotion of Vascepa and to maintain patent protection
for Vascepa. Among the factors that could cause actual results to
differ materially from those described or projected herein include
the following: uncertainties associated generally with research and
development, clinical trials and related regulatory approvals; the
risk that historical REDUCE-IT event rates may not be predictive of
future results and related cost may increase beyond expectations;
the risk that regulatory reviews may alter current expectations
related thereto; the risk that future legal determinations and
interactions with regulatory authorities may impact Vascepa
marketing and sales rights and efforts; the risk that Vascepa may
not show clinically meaningful effects in REDUCE-IT or support
regulatory approvals for cardiovascular risk reduction; and the
risk that patents may not be upheld in patent litigation. A
further list and description of these risks, uncertainties and
other risks associated with an investment in Amarin can be found in
Amarin’s filings with the U.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Amarin undertakes no obligation to update
or revise the information contained in this press release, whether
as a result of new information, future events or circumstances or
otherwise.
Availability of other information about
Amarin
Investors and others should note that we communicate with our
investors and the public using our company website
(www.amarincorp.com), our investor relations website
(http://investor.amarincorp.com), including but not limited to
investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that we post on these
channels and websites could be deemed to be material
information. As a result, we encourage investors, the media,
and others interested in Amarin to review the information that we
post on these channels, including our investor relations website,
on a regular basis. This list of channels may be updated from
time to time on our investor relations website and may include
social media channels. The contents of our website or these
channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
|
|
|
|
|
|
|
CONSOLIDATED BALANCE SHEET DATA |
|
|
(U.S. GAAP) |
|
|
Unaudited |
|
|
|
|
|
|
|
|
|
|
|
June 30, 2017 |
|
December 31, 2016 |
|
|
|
|
(in thousands) |
|
|
ASSETS |
|
|
|
|
|
|
Current
Assets: |
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
85,464 |
|
|
$ |
98,251 |
|
|
|
Restricted cash |
|
|
600 |
|
|
|
600 |
|
|
|
Accounts
receivable, net |
|
|
37,475 |
|
|
|
19,985 |
|
|
|
Inventory |
|
|
24,814 |
|
|
|
20,507 |
|
|
|
Prepaid
and other current assets |
|
|
2,076 |
|
|
|
6,983 |
|
|
|
Total current assets |
|
|
150,429 |
|
|
|
146,326 |
|
|
|
|
|
|
|
|
|
|
Property,
plant and equipment, net |
|
|
52 |
|
|
|
78 |
|
|
|
Deferred
tax assets |
|
|
11,082 |
|
|
|
11,082 |
|
|
|
Other
long-term assets |
|
|
173 |
|
|
|
741 |
|
|
|
Intangible asset, net |
|
|
8,449 |
|
|
|
8,772 |
|
|
|
TOTAL ASSETS |
|
$ |
170,185 |
|
|
$ |
166,999 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
Current
Liabilities: |
|
|
|
|
|
|
Accounts
payable |
|
$ |
16,455 |
|
|
$ |
6,062 |
|
|
|
Accrued
expenses and other current liabilities |
|
|
49,102 |
|
|
|
37,720 |
|
|
|
Current
portion of exchangeable senior notes, net of discount |
|
|
455 |
|
|
|
15,351 |
|
|
|
Current
portion of long-term debt from royalty-bearing instrument
|
|
|
18,833 |
|
|
|
15,944 |
|
|
|
Deferred
revenue, current |
|
|
1,447 |
|
|
|
1,172 |
|
|
|
Total current liabilities |
|
|
86,292 |
|
|
|
76,249 |
|
|
|
|
|
|
|
|
|
|
Long-Term
Liabilities: |
|
|
|
|
|
|
Exchangeable senior notes, net of discount |
|
|
28,884 |
|
|
|
— |
|
|
|
Long-term
debt from royalty-bearing instrument |
|
|
79,283 |
|
|
|
85,155 |
|
|
|
Deferred
revenue, long-term |
|
|
13,332 |
|
|
|
13,943 |
|
|
|
Other
long-term liabilities |
|
|
1,158 |
|
|
|
710 |
|
|
|
Total liabilities |
|
|
208,949 |
|
|
|
176,057 |
|
|
|
|
|
|
|
|
|
|
Stockholders’ Deficit: |
|
|
|
|
|
|
Preferred
stock |
|
|
24,364 |
|
|
|
24,364 |
|
|
|
Common
stock |
|
|
208,556 |
|
|
|
207,166 |
|
|
|
Additional paid-in capital |
|
|
970,797 |
|
|
|
964,914 |
|
|
|
Treasury
stock |
|
|
(3,902 |
) |
|
|
(1,498 |
) |
|
|
Accumulated deficit |
|
|
(1,238,579 |
) |
|
|
(1,204,004 |
) |
|
|
Total stockholders’ deficit |
|
|
(38,764 |
) |
|
|
(9,058 |
) |
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
$ |
170,185 |
|
|
$ |
166,999 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS
DATA |
|
|
(U.S. GAAP) |
|
|
Unaudited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
Six months ended June 30, |
|
|
|
|
(in thousands, except per share
amounts) |
|
(in thousands, except per share
amounts) |
|
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue, net |
$ |
44,948 |
|
|
$ |
32,815 |
|
|
$ |
79,292 |
|
|
$ |
58,122 |
|
|
|
Licensing revenue |
|
293 |
|
|
|
296 |
|
|
|
586 |
|
|
|
532 |
|
|
|
Total revenue, net |
|
45,241 |
|
|
|
33,111 |
|
|
|
79,878 |
|
|
|
58,654 |
|
|
|
Less: Cost
of goods sold |
|
11,401 |
|
|
|
8,861 |
|
|
|
19,599 |
|
|
|
15,757 |
|
|
|
Gross margin |
|
33,840 |
|
|
|
24,250 |
|
|
|
60,279 |
|
|
|
42,897 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative (1) |
|
31,545 |
|
|
|
26,066 |
|
|
|
65,716 |
|
|
|
54,086 |
|
|
|
Research and development (1) |
|
13,694 |
|
|
|
12,578 |
|
|
|
24,517 |
|
|
|
26,308 |
|
|
|
Total operating expenses |
|
45,239 |
|
|
|
38,644 |
|
|
|
90,233 |
|
|
|
80,394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
(11,399 |
) |
|
|
(14,394 |
) |
|
|
(29,954 |
) |
|
|
(37,497 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on change in fair value of derivative liabilities (2)
|
|
— |
|
|
|
5,810 |
|
|
|
— |
|
|
|
4,560 |
|
|
|
Interest expense, net |
|
(2,315 |
) |
|
|
(5,616 |
) |
|
|
(4,696 |
) |
|
|
(11,202 |
) |
|
|
Other income (expense), net |
|
80 |
|
|
|
(182 |
) |
|
|
75 |
|
|
|
(303 |
) |
|
|
Loss from operations before taxes |
|
(13,634 |
) |
|
|
(14,382 |
) |
|
|
(34,575 |
) |
|
|
(44,442 |
) |
|
|
Benefit from income taxes |
|
— |
|
|
|
1,028 |
|
|
|
— |
|
|
|
1,317 |
|
|
|
Net loss |
$ |
(13,634 |
) |
|
$ |
(13,354 |
) |
|
$ |
(34,575 |
) |
|
$ |
(43,125 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
(0.05 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.23 |
) |
|
|
Diluted |
$ |
(0.05 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.23 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
270,725 |
|
|
|
184,471 |
|
|
|
270,445 |
|
|
|
184,262 |
|
|
|
Diluted |
|
270,725 |
|
|
|
184,471 |
|
|
|
270,445 |
|
|
|
184,262 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Excluding non-cash stock-based compensation,
selling, general and administrative expenses were $28,478 and
$23,173 for the three months ended June 30, 2017 and 2016,
respectively, and research and development expenses were $13,136
and $12,106, respectively, for the same periods. Excluding non-cash
stock-based compensation as well as co-promotion fees paid to our
U.S. co-promotion partner, selling, general and administrative
expenses were $23,909 and $18,622 for the three months ended June
30, 2017 and 2016, respectively. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Non-cash gains and losses result from changes
in the fair value of long-term debt derivative
liabilities. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amarin contact information:
Investor Relations:
Elisabeth Schwartz
Investor Relations and Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries:
Ovidio Torres
Finn Partners
In U.S.: +1 (312) 329-3911
Ovidio.torres@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From May 2023 to May 2024